Establishment of a method for measuring plasma sCLEC-2 and its clinical application aiming to prevent arterial thrombosis

我们假设血浆可溶性clc -2浓度是体内血小板活化的良好标志物，它可能是预防和治疗心肌和脑梗死的有用生物标志物。我们建立了ELISA系统检测sclc -2，发现sclc -2是在血小板活化后产生的。此外，急性冠状动脉综合征患者血浆sclc -2显著升高，提示sclc -2是预防和治疗动脉血栓形成的有用生物标志物。

We hypothesized that concentration of plasma soluble CLEC-2 is a good marker for platelet activation in vivo and that it could be a useful biomarker for prevention and treatment for myocardial and cerebral infarction. We established ELISA system to measure sCLEC-2 and found that sCLEC-2 isgenerated upon platelet activation. Moreover, plasma sCLEC-2 is significantly increased in patients of acute coronary syndrome, suggesting that sCLEC-2 is a useful biomarker for prevention and treatment for arterial thrombosis.